BioSpace News Archive

Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints observed at 24 weeks

Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide

Allergan plc announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada.

As part of its commitment to help build more resilient, healthy and sustainable communities across Canada, The Co-operators has renewed its partnership with Working for Change, donating a total of $90,000 over three years to support employment and training opportunities for people marginalized by mental health issues.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies, known as “SLEEP,” in San Antonio from June 8-12, 2019.

Select Medical Corporation (NYSE: SEM) today announced a joint venture agreement with Alternate Solutions Health Network (ASHN) to bring home health and hospice services to its patients and families in select markets nationwide.

MTF Biologics, a leading nonprofit tissue bank dedicated to healing and saving lives, will feature its extensive cosmetic surgery portfolio at this year’s Symposium for Cosmetic Advances & Laser Education (SCALE) 2019, May 9-11, 2019, at the Music City Center in Nashville, Tennessee.

UroGen Pharma Ltd. announced financial results for the first quarter ended March 31, 2019 and provided an overview of the Company’s recent developments.

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Company”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, announced today its 2nd annual workshop, titled, ‘Process Considerations for Cryogenic and Regenerative Medicine Commercialization,’ taking place on Wednesday, May 15, 2019

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress.